Clinical Trials | November 27, 2025
NHS’s breakthrough leukaemia therapy set to transform lives in UK
Clinical trials found that 77% of patients went into remission after receiving obe-cel
Clinical trials found that 77% of patients went into remission after receiving obe-cel
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
OS is a key secondary endpoint of the 948-patient study, which is evaluating whether adding AstraZeneca's PD-L1 inhibitor to standard FLOT chemotherapy
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
Subscribe To Our Newsletter & Stay Updated
